RPL13A - middle region Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-RPL13A - middle region antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityRPL13A - middle region
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formataffinity purified
Size0.1 mL
Concentrationn/a
ApplicationsWestern Blot (WB)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionRibosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a member of the L13P family of ribosomal proteins that is a component of the 60S subunit. The encoded protein also plays a role in the repression of inflammatory genes as a component of the IFN-gamma-activated inhibitor of translation (GAIT) complex. This gene is co-transcribed with the small nucleolar RNA genes U32, U33, U34, and U35, which are located in the second, fourth, fifth, and sixth introns, respectively. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogen
ImmunogenImmunogen: The immunogen is a synthetic peptide directed towards the middle region of human RPL13A
Other Names[60S ribosomal protein L13a isoform 2; 60S ribosomal protein L13a; 60S ribosomal protein L13a; ribosomal protein L13a; 23 kDa highly basic protein]
Gene, Accession #[RPL13A], Gene ID: 23521, NCBI: NP_001257420.1, UniProt: P40429
Catalog #MBS3221668
Price$335
Order / More InfoRPL13A - middle region Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.